Eiger BioPharmaceuticals, Celladon Announce Merger Agreement; Investor Syndicate to Invest $39.5M In Combined Co

Celladon Corporation CLDN and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company announced Wednesday, that they have entered into a definitive merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined. The proposed merger remains subject to certain conditions, including the approval of Celladon stockholders.  If approved, upon closing of the transaction, Celladon will be renamed Eiger BioPharmaceuticals, Inc. An investor syndicate has committed to invest $39.5 million in the combined company including new investors HBM Healthcare Investments, RA Capital Management, Sabby Management, Sphera Global Healthcare, Perceptive Advisors and Monashee Capital Partners together with existing long-time Eiger stockholders, ViVo Capital and InterWest Partners.  Six million dollars of the financing has already been funded, and the See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsM&APress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!